Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer

Nuclear Medicine Communications

Volumn 32, Issue 6, 2011, Pages 460-465

  Kameyama, Reiko ^a   Yamamoto, Yuka ^a   Izuishi, Kunihiko ^a   Sano, Takanori ^a   Nishiyama, Yoshihiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

3 deoxy 3 18F fluorothymidine; equilibrative nucleoside transporter 1; gastrointestinal cancer; positron emission tomography; thymidine kinase 1

Indexed keywords

3' FLUOROTHYMIDINE F 18; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; MESSENGER RNA; THYMIDINE KINASE 1; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; STOMACH CANCER; CLINICAL TRIAL; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTISCANNING; STATISTICAL MODEL; TRANSPORT AT THE CELLULAR LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; DIDEOXYNUCLEOSIDES; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE KINASE;

EID: 79955551686     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834209b5     Document Type: Article

References (25)

1. Costa A, Silvestrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, et al. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer 1996; 73:914-919. (Pubitemid 26110163)
2. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332. (Pubitemid 38552885)
3. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn- Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998; 4:1334-1336. (Pubitemid 28512118)
4. Plagemann PG, Richey DP, Zylka JM, Erbe J. Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment. Exp Cell Res 1974; 83:303-310.
5. Hopwood LE, Dewey WC, Hejny W. Transport of thymidine during the cell cycle in mitotically synchronized CHO cells. Exp Cell Res 1975; 96:425-429.
6. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 30-deoxy-30-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 2004; 31:829-837. (Pubitemid 39297680)
7. Rasey JS, Grierson JR,Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43:1210-1217. (Pubitemid 34988769)
8. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52:1602-1606. (Pubitemid 37363445)
9. Buck AK, Halter G, Schirrmeister H, Kotzerke J,Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44:1426-1431. (Pubitemid 39663355)
10. Van Westreenen HL, Cobben DC, Jager PL, An Dullemen HM,Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46:400-404. (Pubitemid 43093146)
11. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30:1407-1412. (Pubitemid 37247960)
12. Smyczek-Gargya B, Fersis N, Dittmann H, Eichhorn K, Eschmann SM, Horger M, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31:720-724. (Pubitemid 38647912)
13. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 2007; 48:1945-1950. (Pubitemid 350232302)
14. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M, Murota M, et al. Detection of gastric cancer using 18F-FLT PET: comparison with 18FFDG PET. Eur J Nucl Med Mol Imaging 2009; 36:382-388.
15. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F] 30-deoxy-30-fluorothymidine versus [18F]fluoro- 2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994. (Pubitemid 37086941)
16. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [18F]30-deoxy-30-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007; 34:878-883. (Pubitemid 46798949)
17. Yamamoto Y, Kameyama R, Izuishi K, Takebayashi R, Hagiike M, Asakura M, et al. Detection of colorectal cancer using 18F-FLT PET: comparison with 18F-FDG PET. Nucl Med Commun 2009; 30:841-845.
18. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44:2027-2032. (Pubitemid 40022149)
19. Machulla HJ, Blocher A, Kuntzsch M, Piert M,Wei R, Grierson JR. Simplified labeling approach for synthesizing 30-deoxy-30-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000; 24:843-846. (Pubitemid 30462551)
20. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 2000; 60:6201-6207.
21. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleosides transporters in normal and tumor tissue. Biochem Biophys Res Commun 2001; 280:951-959. (Pubitemid 32924526)
22. Reske SN, Deisenhofer S. Is 30-deoxy-30-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 2006; 33:S38-S43.
23. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995; 35:69-89.
24. Munch-Petersen B, Tyrsted G, Cloos L. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzyme properties. J Biol Chem 1993; 268:15621-15625. (Pubitemid 23222058)
25. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 30-deoxy-30-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63:3791-3798. (Pubitemid 36793068)